NEUROPACE NPCE 深 沪
等待开盘 08-14 09:30:00 美东时间
9.32
+0.190
+2.08%
华盛通- 最 高9.6788
- 今 开8.95
- 成交量 41.67万股
- 最 低 7.5625
- 昨 收 9.13
- 总市值 3.06亿
- 52周最高 18.975
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.45
- 委 比 82.68%
- 总股本 3279.85万
- 历史最高 27.38
- 量 比 2.34
- 振 幅 23.18%
- 历史最低 1.22
- 每 手 1
- 风险率 2.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroPace上调2025年营收指引
专注于神经系统疾病治疗创新方案的医疗设备公司NeuroPace（NPCE）将2025年营收指引上调至9400-9800万美元，主要得益于其RNS系统销售强劲...
08-13 22:33
Wells Fargo Maintains Overweight on NeuroPace, Lowers Price Target to $15
Wells Fargo analyst Vik Chopra maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $17 to $15.
08-13 20:42
电话会总结 ｜ NeuroPace(NPCE)2025财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• ### 1. 财务业绩：- **营收（Revenue）：** NeuroPace 2025年第二季度实现营收2350万美元，同比增长22%（2024年同期为1930万美元）。增长主要得益于核心RNS系统销售的持续强劲表现，以及植入量和处方医生活动的增加。 - **毛利率（Gross Margin）：** 第二季度毛利率为77.1%，高于2024年同期的73.4%。RNS系统的毛利率超过80%，得益于销售组合优化、制造效率提升以及平均销售价格的提高。 - **运营亏损（Operating Loss）：** 第二季度运营亏损为680万美元，相较于2024
08-13 12:05
NeuroPace Raises FY2025 Sales Guidance from $93.00M-$97.00M to $94.00M-$98.00M vs $94.82M Est
NeuroPace (NASDAQ:NPCE) raises FY2025 sales outlook from $93.00 million-$97.00 million to $94.00 million-$98.00 million vs $94.82 million estimate.
08-13 04:08
NeuroPace Q2 EPS $(0.26) Misses $(0.23) Estimate, Sales $23.52M Beat $23.09M Estimate
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.23) by 15.56 percent. This is unchanged from the same period last year. The company reported
08-13 04:08
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
NeuroPace, Inc., a medical technology company focused on treating epilepsy, issued a statement responding to the Centers for Medicare & Medicaid Services (CMS) decision not to finalize the reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule. Joel Becker, CEO of NeuroPace, expressed appreciation for CMS maintaining the current MS-DRG assignment for RNS® System procedures under MS-DRG ...
08-01 11:30
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
NeuroPace, Inc. will report its Q2 2025 financial results after market close on August 12, 2025, followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET). Investors can access the call via webcast at [link] or by phone (+1-877-407-3982, Conference ID: 13754370). The webcast will be archived for 90 days on the company’s investor relations website.
07-29 20:05
NeuroPace Appoints New CFO Amid Strategic Shift
NeuroPace ( ($NPCE) ) has shared an announcement. On June 20, 2025, Rebecca Kuh...
06-25 04:29
NeuroPace appoints Patrick Williams as CFO
NeuroPace (NASDAQ:NPCE) has announced the appointment of Mr. Patrick F. Williams as CFO, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Co. to depart from her CFO rol...
06-25 04:09
